An update from Suzhou Basecare Medical Corp. Ltd. Class H ( (HK:2170) ) is now available.
Suzhou Basecare Medical Corp. Ltd. announced its audited consolidated results for the year ended December 31, 2024, showing a revenue increase to RMB 299,109,000 from RMB 207,976,000 in 2023, despite a loss for the year amounting to RMB 237,210,000. The company continues to expand its product pipeline through independent R&D and mergers and acquisitions, establishing itself as a key player in the global assisted reproduction industry by providing full-industry products at competitive prices, thereby contributing to human reproductive health.
More about Suzhou Basecare Medical Corp. Ltd. Class H
Suzhou Basecare Medical Corp. Ltd. is an innovative medical device provider specializing in assisted reproduction in China. The company focuses on developing automatic, standard, and intelligent assisted reproduction products, aiming to enhance the success rate and efficiency of reproductive procedures. Their offerings include a comprehensive range of reagents, consumables, instruments, and equipment, supported by continuous innovation and clinical feedback.
YTD Price Performance: 31.75%
Average Trading Volume: 158,503
Technical Sentiment Signal: Sell
Current Market Cap: HK$1.02B
For an in-depth examination of 2170 stock, go to TipRanks’ Stock Analysis page.